These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2017999)

  • 21. [Delayed-action disopyramide in the treatment of hyperkinetic ventricular arrhythmia. A randomized clinical comparative study vs immediate-action disopyramide].
    Romanò M; Spinelli A; Cazzani E; Muzio L
    Clin Ter; 1991 Jul; 138(1):13-9. PubMed ID: 1834395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias.
    Stewart DE; Ikram H
    N Z Med J; 1984 Mar; 97(751):148-50. PubMed ID: 6584758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of ventricular arrhythmias by United States cardiologists: a survey before the Cardiac Arrhythmia Suppression Trial results were available.
    Morganroth J; Bigger JT; Anderson JL
    Am J Cardiol; 1990 Jan; 65(1):40-8. PubMed ID: 1688481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disopyramide-induced ventricular fibrillation.
    Nicholson WJ; Martin CE; Gracey JG; Knoch HR
    Am J Cardiol; 1979 May; 43(5):1053-5. PubMed ID: 433766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical studies of Norpace (Part VI).
    Pugh DM
    Angiology; 1975 Jan; 26(1 Pt 2):142. PubMed ID: 803799
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term use of controlled-release disopyramide in patients with severe ventricular arrhythmias.
    Paulk EA
    Angiology; 1987 Feb; 38(2 Pt 2):198-204. PubMed ID: 3103494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical and hemodynamic effects of disopyramide phosphate administered i.v. in cardiopathic subjects (author's transl)].
    Chiariello M; Santinelli V; Ferro G; Tari MG; Stanislao M; Condorelli M
    G Ital Cardiol; 1979; 9(9):975-83. PubMed ID: 520746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of an anti-arrhythmic agent, disopyramide, in delayed action form ('Ritmoforine' Retard).
    Nauta IL; van de Calseyde JF
    Curr Med Res Opin; 1981; 7(4):215-26. PubMed ID: 7226872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term therapy with disopyramide phosphate: side effects and effectiveness.
    Bauman JL; Gallastegui J; Strasberg B; Swiryn S; Hoff J; Welch WJ; Bauernfeind RA
    Am Heart J; 1986 Apr; 111(4):654-60. PubMed ID: 3082173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical studies of Norpace (Part X).
    Dreifus LS
    Angiology; 1975 Jan; 26(1 Pt 2):148. PubMed ID: 46728
    [No Abstract]   [Full Text] [Related]  

  • 31. Disopyramide (Norpace) for ventricular arrhythmias.
    Med Lett Drugs Ther; 1977 Dec; 19(25):101-2. PubMed ID: 593226
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antiarrhythmic action of disopyramide: a study of plasma levels].
    Page A; Pic A; Besse P
    Arch Mal Coeur Vaiss; 1979 Jul; 72(7):774-80. PubMed ID: 117775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Place of disopyramide in relieving ectopic arrhythmia].
    Smolenskiĭ VS; Fomina IG; Abunder AA; Kulikova LA; Vasil'eva VL
    Klin Med (Mosk); 1987 Jan; 65(1):43-5. PubMed ID: 3550282
    [No Abstract]   [Full Text] [Related]  

  • 34. [Use of intravenous disopyramide in the treatment of symptomatic refractory ventricular arrhythmia].
    Leone A
    Minerva Cardioangiol; 1984 Mar; 32(3):151-6. PubMed ID: 6728204
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical pharmacokinetics and effects of an oral sustained-release preparation of disopyramide prescribed for patients undergoing maintenance hemodialysis.
    Kaji T; Nojima Y; Arisaka H; Naruse T
    Blood Purif; 2000; 18(1):55-8. PubMed ID: 10686443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity.
    Meltzer RS; Robert EW; McMorrow M; Martin RP
    Am J Cardiol; 1978 Dec; 42(6):1049-53. PubMed ID: 727132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
    Boudonas G; Lefkos N; Efthymiadis AP; Styliadis IG; Tsapas G
    Acta Cardiol; 1995; 50(2):125-34. PubMed ID: 7610735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician attitudes toward the use of type IC antiarrhythmics after the Cardiac Arrhythmia Suppression Trial (CAST).
    Reiffel JA; Cook JR
    Am J Cardiol; 1990 Nov; 66(17):1262-4. PubMed ID: 2122707
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical studies of Norpace. Summarizing remarks.
    Fowler NO
    Angiology; 1975 Jan; 26(1 Pt 2):154-5. PubMed ID: 1090216
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.